For years, French Carbios SAS has worked to set up a process that effectively depolymerizes PET, one of the most common plastics. Now its process has been published.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2020-04-15_um_08.33.32.png437707Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-04-15 08:07:112020-04-15 08:07:11Carbios SAS publishes PET recycling technology
https://european-biotechnology.com/wp-content/uploads/2024/04/Mobidiag_Tecan.jpg370720Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-04-14 09:29:512020-04-14 09:29:51Mobidiag’s COVID-19 test okayed for emergency use
https://european-biotechnology.com/wp-content/uploads/2024/04/2020_04_13_EBM_800px-Pseudomonas_CDC_sw_Kopie.jpg433769Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-04-13 00:45:592024-04-02 16:20:33Is AMR the next, but hidden, crisis?
Every year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 deliver windfall surprises for European names?
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2020-04-08 10:07:502020-04-08 10:07:50Sutura Therapeutics: New CEO
Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
https://european-biotechnology.com/wp-content/uploads/2024/04/Lady_with_Solnatide_vials_in_production.jpg19251921Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-04-08 09:20:562020-04-08 09:20:56COVID-19: Solnatide approved for compassionate use
In October 2019, Thierry Bernard provisionally took over the responsibilities of Qiagen CEO Peer Schatz, who had left the company unexpectedly after 27 years.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2020-04-01 12:16:342020-04-01 12:16:34Qiagen: Thierry Bernard remains CEO
Carbios SAS publishes PET recycling technology
Latest NewsFor years, French Carbios SAS has worked to set up a process that effectively depolymerizes PET, one of the most common plastics. Now its process has been published.
Mobidiag’s COVID-19 test okayed for emergency use
Latest NewsMolecular diagnostics specialist Mobidiag Ltd has got emergency approval for its Amplidiag® COVID-19 molecular diagnostic test in Finland.
Is AMR the next, but hidden, crisis?
BackgroundWith the coronavirus pandemic mounting, experts are warning of AMR as being the next, hidden crisis.
Researchers reconstruct SARS-CoV-2 evolution
Latest NewsBritish researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US.
European assets ahead despite virus panic
OpinionEvery year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 deliver windfall surprises for European names?
Sutura Therapeutics: New CEO
AppointmentsMark Beards is the new CEO of Sutura Therapeutics Ltd in Birkenhead (UK).
COVID-19: Solnatide approved for compassionate use
Latest NewsAustrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
GE renamed Cytiva upon take-over by Danaher
Latest NewsMaking opoids more effective pain killers
Latest NewsLow intrinsic efficacy can explain the reduced side effects of new agonists of the m-opioid receptor a British-Australian reseach team reports.
Qiagen: Thierry Bernard remains CEO
AppointmentsIn October 2019, Thierry Bernard provisionally took over the responsibilities of Qiagen CEO Peer Schatz, who had left the company unexpectedly after 27 years.